Defactinib analogue-1 (Compound 7) 作为一种靶向Fak的配体，可用于PROTAC FAK degrader 1的合成。

Body Protection Compound 157 (BPC 157) is a pentadecapeptide derived from BPC, identified in gastric juice, exhibiting diverse biological activities. At 2 µg/ml, BPC 157 enhances primary rat tendon fibroblast cell migration and F-actin formation. Furthermore, doses of 0.01 and 10 µg/kg, intraperitoneally (i.p.), mitigate paw swelling, bone erosion, and mononuclear cell infiltration in the joints of rats with rheumatoid arthritis induced by complete Freund's adjuvant (CFA). It also diminishes gastric ulcer size in rats caused by indomethacin, aspirin, or diclofenac at these doses. Additionally, BPC 157 reduces catalepsy duration and tremor severity in a mouse model of Parkinson's disease triggered by MPTP.

FLT3-IN-17 是一种 FAK 抑制剂 (IC50: 12 nM)。FLT3-IN-17 能够抑制 CYPs 和 FLT3 突变体的活性，对 D835Y 的 IC50<0.5 nM。FLT3-IN-17 能够用于癌症的研究。

Petunidin chloride has antioxidant, and anti-carcinogenesis activities.

BPC 157 is a 15-amino acid fragment of a gastric peptide (BPC) which has hepatoprotective effects.

PDZ1i 是有效的、能够透过血脑屏障的 MDA-9/Syntenin 特异性抑制剂。PDZ1i 能够抑制关键的 GBM (多形性成胶质细胞瘤)信号，包括 FAK 及 EGFRvIII，并能够减少 MMP 分泌。PDZ1i 可以提高患脑瘤小鼠的生存率并减少肿瘤的侵袭。